Eli Lilly embarks on record $20B+ acquisition spree in 2026
Eli Lilly & Co. has announced acquisitions worth more than $20 billion in 2026, a record spending spree as the drugmaker expands beyond its obesity franchise.
Quick reaction
One tap helps tune what we surface next.
Reader discussion
Public commentsNo comments yet. Start the discussion around this signal.
Follow this signal
Get updates on this story
We will email you if this changes materially. No spam. Daily brief optional.
Map context
See this on the live map
Keep the story in context with nearby live signals, countries, and category movement.
Related coverage
More story pages
Applied Aerospace & Defense targets $3.59 billion valuation in US IPO
Applied Aerospace & Defense is targeting a $3.59 billion valuation in its upcoming US initial public offering, according to Reuters.
Xiaomi posts 43% Q1 net-profit slump on high chip costs, EV unit revenue at $2.8B but drags on earnings
Xiaomi reported a 43% drop in first-quarter net profit due to high memory-chip costs, while its electric vehicle unit contributed $2.8 billion in revenue but weighed on earnings because of heavy investment.
Russian court orders immediate enforcement of damages recovery from Euroclear at Central Bank's request
Court grants Russian Central Bank's request for immediate enforcement of decision on recovery of damages from Euroclear
VTB recommends record dividend of 9.71 rubles per share, proposes additional share placement. Shares drop 8.44% on the news.
VTB's supervisory board recommended a dividend of 9.71 rubles per share, with a yield of up to 11%. Total payout is 125.5 billion rubles, representing 25% of 2025 IFRS net profit. The board also proposed discussing an additional share issue. VTB shares fell 8.44% to 79.345 rubles on the news.
More live signals
Continue with the live feed.
The fastest nearby updates load from the public feed, not the enriched story endpoint.